{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:01:50Z","timestamp":1770969710636,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1136\/ard.2004.033225","type":"journal-article","created":{"date-parts":[[2005,2,11]],"date-time":"2005-02-11T18:28:43Z","timestamp":1108146523000},"page":"ii93-ii100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S2","title":["Psoriatic arthritis and psoriasis: role of patient advocacy organisations in the twenty first century"],"prefix":"10.1016","volume":"64","author":[{"given":"G M","family":"Zimmerman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L M","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D C","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Maccarone Buonfigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2004.033225_bib1","series-title":"Benchmark Survey","author":"National Psoriasis Foundation","year":"2001"},{"key":"10.1136\/ard.2004.033225_bib2","series-title":"Internal Statistical Report","author":"National Psoriasis Foundation","year":"2004"},{"key":"10.1136\/ard.2004.033225_bib3","series-title":"Survey Panels","author":"National Psoriasis Foundation","year":"2004"},{"key":"10.1136\/ard.2004.033225_bib4","series-title":"Survey Panels","author":"National Psoriasis Foundation","year":"2003"},{"key":"10.1136\/ard.2004.033225_bib5","series-title":"Straight Talk on Spondylitis","author":"Spondylitis Association of America (SAA)","year":"1992"},{"key":"10.1136\/ard.2004.033225_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00002281-200007000-00002","article-title":"Scientific contributions of ankylosing spondylitis patient advocacy groups","volume":"12","author":"Feldkeller","year":"2000","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2004.033225_bib7","author":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)"},{"key":"10.1136\/ard.2004.033225_bib8","unstructured":"Bruckel J. Spondylitis Association of America. Presented at investigators meeting on AS, New York 28 August 2002."},{"key":"10.1136\/ard.2004.033225_bib9","unstructured":"Diagnosis and management of ankylosing spondylitis, guidelines in rheumatology. A CME enduring material developed to review recent guidelines regarding the assessment and treatment of ankylosing spondylitis. Release date: March 2004; Termination date: March 2005. Supported by an unrestricted grant from Amgen, Inc and Wyeth."},{"key":"10.1136\/ard.2004.033225_bib10","first-page":"2","article-title":"Spondylitis Association of America","volume":"5","year":"2004","journal-title":"Spondylitis Plus"},{"key":"10.1136\/ard.2004.033225_bib11","first-page":"9","volume":"Fall","author":"Spondylitis Association of America","year":"1999","journal-title":"Spondylitis Plus"},{"key":"10.1136\/ard.2004.033225_bib12","author":"National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"key":"10.1136\/ard.2004.033225_bib13","unstructured":"Spondylitis Association of America, Annual Membership Survey, 2001\u20132002."},{"key":"10.1136\/ard.2004.033225_bib14","first-page":"1","article-title":"Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Genetic and gender effects","volume":"16","author":"Gladman","year":"1993","journal-title":"Clin Invest Med"},{"issue":"suppl II","key":"10.1136\/ard.2004.033225_bib15","first-page":"ii18","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.033225_bib16","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1517\/14656566.5.9.1881","article-title":"Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis","volume":"5","author":"Merkesdal","year":"2004","journal-title":"Expert Opin Pharmacother"},{"issue":"suppl","key":"10.1136\/ard.2004.033225_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00019053-200422001-00006","article-title":"Review of health economics modelling in rheumatoid arthritis","volume":"22","author":"Emery","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1136\/ard.2004.033225_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11926-996-0010-x","article-title":"Recent advances in the treatment of the seronegative spondyloarthropathies","volume":"3","author":"Ritchlin","year":"2001","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/ard.2004.033225_bib19","unstructured":"Spondylitis Association of America. AS Life Impact Study, 2002."},{"key":"10.1136\/ard.2004.033225_bib20","series-title":"Patient and Public Involvement in Health\u2014The Evidence for Policy Implementation","author":"Farrell","year":"2004"},{"key":"10.1136\/ard.2004.033225_bib21","series-title":"The NHS Plan implementation programme 2001\u20132","author":"Department of Health","year":"2000"},{"key":"10.1136\/ard.2004.033225_bib22","series-title":"Internal Statistical Report","author":"Psoriatic Arthritis Alliance","year":"2003"},{"key":"10.1136\/ard.2004.033225_bib23","unstructured":"TOPSO Study. Skin \u2018n' Bones Connection, 2004;4."},{"key":"10.1136\/ard.2004.033225_bib24","series-title":"The NHS Improvement Plan: Putting people at the heart of public services","author":"Department of Health","year":"2004"},{"key":"10.1136\/ard.2004.033225_bib25","unstructured":"Italian Law N .226, November 1999."},{"key":"10.1136\/ard.2004.033225_bib26","first-page":"1727","article-title":"The utility of the arthritis impact measurement scales for patients with psoriatic arthritis","volume":"19","author":"Duffy","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.033225_bib27","first-page":"439","article-title":"A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis","volume":"13","author":"Husted","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2004.033225_bib28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.0022-202X.2004.22524.x","article-title":"Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population","volume":"122","author":"Giardina","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard.2004.033225_bib29","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2001.01311.x","article-title":"Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21","volume":"116","author":"Capon","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard.2004.033225_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00296-002-0242-7","article-title":"Ankylosing spondylitis in the pharaohs of ancient Egypt","volume":"23","author":"Feldtkeller","year":"2003","journal-title":"Rheumatol Int"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724424242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724424242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2004.033225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T05:15:06Z","timestamp":1737263706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724424242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":30,"alternative-id":["S0003496724424242"],"URL":"https:\/\/doi.org\/10.1136\/ard.2004.033225","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriatic arthritis and psoriasis: role of patient advocacy organisations in the twenty first century","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2004.033225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Copyright 2005 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}